Takeda Submits Application For Fixed-Dose Blopress And Diuretic Combination In Japan
This article was originally published in PharmAsia News
Executive Summary
Takeda Pharmaceutical submitted a new drug application for a fixed-dose combination tablet of Blopress (candesartan cilexetil) and diuretic (hydrochlorothiazide) for treatment of hypertension to Japan's Ministry of Health, Labor and Welfare. Launched in 1999, Blopress is an angiotensin II receptor blocker and has become the first ARB indicated for chronic heart failure in Japan. Hydrochlorothiazide is classified as a thiazide diuretic and lowers blood pressure by increasing the flow of urine. Takeda's Development Division General Manager Masaomi Miyamoto said the application will maximize the value of Blopress. Currently, Takeda has fixed-dose combinations of Actos with sulfonylurea, and Actos with biganide, which are being marketed overseas. (Click here for more - Japanese language